The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer

11 May 2022 In Allies & Partnerships, News

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that its Board of Directors appointed Marc Hurlbert, PhD, as its new Chief Executive Officer.

Read More


Dr. Gary Deng & The Wellness Principles

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 9 May 2022 In Allies & Partnerships, Prevention, Treatment

Gary Deng, MD, PhD – an integrative medicine specialist at Memorial Sloan Kettering Cancer Center – knows this firsthand. And now, for the first time, Dr. Deng is sharing his unique and highly respected wellness approach with everyone through his upcoming book, The Wellness Principles – Cooking for a Healthy Life.

Read More


Why I Step - Lynn Merrill Iverson

By Renee Orcione, MRA Development Associate | 25 April 2022 In Allies & Partnerships, Events, Melanoma Stories

In 2021, as part of MRA’s inaugural Step Up for Melanoma challenge, Lynn joined hundreds of supportive and passionate individuals across the country to share Bert’s story, keep his memory alive, raise awareness, and complete 310,000 steps during Melanoma Awareness Month.

Read More


A Message from the Melanoma Research Alliance

21 April 2022 In News

Michael Kaplan, MRA’s President & CEO, will retire on April 30, 2022. Kaplan, who has led the Melanoma Research Alliance since 2016, will be succeeded by Dr. Marc Hurlbert.

Read More


What You Control: Your Microbiome, Diet, Stress, & Melanoma

14 April 2022 In Science

Every day, we hear from patients who want to know what, if anything, they can do to have the best health outcomes possible. For people facing melanoma, it’s common to feel overwhelmed and out of control with everything that a melanoma diagnosis and treatment entail.

Read More


Averting and Treating Immune-related Adverse Events Associated with Checkpoint Immunotherapies

2 April 2022 In Science, Treatment

The first ever immune checkpoint inhibitor was approved by the Food & Drug Administration (FDA) in 2011 with an indication for treating metastatic melanoma. That approval was built upon ground-breaking research by Jim Allison, MRA Scientific Advisory Panel member and 2018 Nobel Laureate.

Read More


Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment

It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.

Read More


MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma

18 March 2022 In News, Science, Treatment

The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.

Read More


Recordings from MRA's 2022 Patient Forum

16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment

MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.

Read More


From Promise to Action: Testing AI in the Clinic

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 8 March 2022 In Prevention, Science

If you browse through your phone’s app store, you’ll find dozens of apps promising to help determine if a mole you’ve been staring at is cancerous or not based on the power of AI. While a great goal, none of these apps have earned approval from the Food and Drug Administration (FDA). However, to do so, apps — and the algorithms that they rely on — will need to be rigorously tested in the real world and across diverse populations. This is exactly where Dr. Novoa’s research is aimed.

Read More


Login

×